Physician profile
Ella Solomon
NPI 1437692480
$24,343.18
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13K · 2022: $5,070 · 2023: $4,354 · 2024: $2,199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,164 · Consulting Fee: $2,054 · Education: $302 · Travel and Lodging: $32.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,163.52 |
| Consulting Fee | $2,054.00 |
| Education | $302.43 |
| Travel and Lodging | $32.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $11,892.83 | 2021-2024 | Ilumya, Winlevi, Absorica Ld |
| E.R. Squibb & Sons, L.L.C. | $3,223.83 | 2021-2024 | Sotyktu |
| Abbvie INC. | $1,948.10 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $1,336.17 | 2021-2024 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $1,328.93 | 2021-2024 | Tremfya, Simponi, Stelara |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,023.50 | 2022-2024 | Spevigo |
| Almirall LLC | $593.60 | 2021-2024 | Klisyri |
| Lilly USA, LLC | $447.30 | 2021-2024 | Taltz, Olumiant |
| Genzyme Corporation | $432.25 | 2021-2023 | |
| Incyte Corporation | $410.82 | 2021-2024 | Opzelura |
| Leo Pharma INC. | $308.21 | 2021-2024 | Adbry |
| Journey Medical Corporation | $249.98 | 2022 | |
| Dermavant Sciences, INC. | $221.03 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $168.41 | 2021-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $159.92 | 2021-2024 | Siliq, Arazlo, Jublia |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $128.53 | 2021-2022 | |
| Biofrontera INC. | $79.99 | 2021-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Mayne Pharma Commercial LLC | $73.96 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $72.00 | 2021 | |
| Amgen INC. | $67.26 | 2022-2023 | Otezla |
| Galderma Laboratories, L.P. | $51.47 | 2021-2024 | Aklief |
| Dermira, INC. | $42.31 | 2021 | |
| Arcutis Biotherapeutics, INC. | $36.22 | 2024 | Zoryve |
| Nabriva Therapeutics, Plc | $28.54 | 2021-2022 | |
| Genentech USA, INC. | $18.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ella Solomon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.